menu
    • menu
    [{"orgOrder":0,"company":"Novozymes","sponsor":"Estimates OY","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bacillus Velezensis DSM 33864","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novozymes \/ Estimates OY","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Estimates OY"},{"orgOrder":0,"company":"Novozymes","sponsor":"University of Aarhus","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"DENMARK","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Enzyme","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novozymes \/ University of Aarhus","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ University of Aarhus"},{"orgOrder":0,"company":"Novozymes","sponsor":"Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"DENMARK","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum DSM 33464","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Novozymes \/ Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center"},{"orgOrder":0,"company":"Novozymes","sponsor":"Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum DSM 33464","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Novozymes \/ Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc"},{"orgOrder":0,"company":"Novozymes","sponsor":"Novozymes","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"IRELAND","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Limosilactobacillus Reuteri","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novozymes \/ Novozymes","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Novozymes"},{"orgOrder":0,"company":"Novozymes","sponsor":"Biofortis M\u00e9rieux Nutriscience","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"NZ-GHMH-01","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novozymes \/ Biofortis M\u00e9rieux Nutriscience","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Biofortis M\u00e9rieux Nutriscience"},{"orgOrder":0,"company":"Novozymes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Polyphenol Oxidase","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novozymes \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Undisclosed"},{"orgOrder":0,"company":"Novozymes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novozymes \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Undisclosed"},{"orgOrder":0,"company":"Novozymes","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novozymes \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Analyze & Realize"},{"orgOrder":0,"company":"Novozymes","sponsor":"University of Aarhus","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novozymes \/ University of Aarhus","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ University of Aarhus"},{"orgOrder":0,"company":"Novozymes","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Limosilactobacillus Reuteri Strain","moa":"Microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novozymes \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Citruslabs"}]

    Find Clinical Drug Pipeline Developments & Deals by Novozymes

    Menu

    Novozymes

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Limosilactobacillus Reuteri Strain

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Citruslabs

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort

                            Details : Limosilactobacillus Reuteri Strain is a Probiotic drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Upper Gastrointestinal Discomfort.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            September 09, 2025

                            Lead Product(s) : Limosilactobacillus Reuteri Strain

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Citruslabs

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Undisclosed

                            Sponsor : University of Aarhus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Enzyme-containing Lozenge on Dental Biofilm Formation, Composition and Functionality

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Dental Plaque.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 21, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Undisclosed

                            Sponsor : University of Aarhus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Analyze & Realize

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of a Combination of Lactase and L. Salivarius DSM 34078 in Individuals With Lactose Intolerance

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Lactose Intolerance.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 30, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Analyze & Realize

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Limosilactobacillus Reuteri

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Recipient : University College Cork

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Symbiont-Restore Study

                            Details : Limosilactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            July 12, 2023

                            Lead Product(s) : Limosilactobacillus Reuteri

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Recipient : University College Cork

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus Velezensis DSM 33864

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Estimates OY

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

                            Details : Bacillus Velezensis DSM 33864 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Clostridium Infections.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            November 04, 2022

                            Lead Product(s) : Bacillus Velezensis DSM 33864

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Estimates OY

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Enzymes on Dental Biofilm Accumulation

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Dental Plaque.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 14, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Plantarum DSM 33464

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Lactobacillus Plantarum DSM 33464 on Blood Lead Levels in Young Women of Child-bearing Age

                            Details : Lactobacillus Plantarum DSM 33464 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Lead Poisoning.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 18, 2022

                            Lead Product(s) : Lactobacillus Plantarum DSM 33464

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : Universidad Iberoamericana A.C., Mexico | Linus Biotechnology Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyphenol Oxidase

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of an Investigational Lozenge (Biofresh® 4plus) Versus Placebo Control on Oral Malodor (Intra-Oral H...

                            Details : Polyphenol Oxidase is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Halitosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 10, 2022

                            Lead Product(s) : Polyphenol Oxidase

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzyme

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Undisclosed

                            Sponsor : University of Aarhus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of an Enzyme-containing Lozenge on Dental Biofilm in Healthy Individuals.

                            Details : This is a Enzyme drug candidate, which is currently being evaluated in clinical studies for the treatment of Dental Plaque.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            October 07, 2021

                            Lead Product(s) : Enzyme

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Undisclosed

                            Sponsor : University of Aarhus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Novozymes

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Plantarum DSM 33464

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Efficacy and Safety of Lactobacillus Plantarum DSM 33464 on Blood Lead Levels in Child...

                            Details : Lactobacillus Plantarum DSM 33464 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Lead Poisoning.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            May 18, 2021

                            Lead Product(s) : Lactobacillus Plantarum DSM 33464

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : Beijing Children's Hospital | Baoding Children's Hospital | Xuzhou Children Hospital | Chengdu Women's and Children's Central Hospital | Children's Hospital of Heibei Province | Beijing Clinical Service Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth